copying the sincierest form of compliment.

Abiomed/SCR (must be related companies?) have a counter-pulsation pump "Symphony" in Phase 1 trials.
Same principles as C-Pulse but blood contacting.
Bad it is a competitor but ***highly, highly positive in that it endorses the principals of C-Pulse****.
Again Symphony is blood contacting so it can't be switched on and off by user and must have all the other dangers associated with blood contact.
Claiming less invasive surgery but must have a graft etc so can't see this.
Limited to short term 90 days at this stage?
Much smaller projected market.
Dr Cecere heavily linked to both C-Pulse and Symphony.

Some links
http://www.scrdevelopmentgroup.com/index.shtmlhttp://phx.corporate-ir.net/phoenix.zhtml?c=95629&p=irol-newsArticle&ID=1654540&highlight=http://www.abiomed.com/products/symphony/
http://www.medicaldevicestoday.com/2012/02/abiomed-touts-advantages-of-new-symphony-partial-support-cardiac-assist-
http://clinicaltrials.gov/ct2/show/NCT01543022?term=Symphony&rank=1